Lysine Specific Demethylase 1 Inhibitors: 2025 Pipeline Insight Report

(MENAFN- GlobeNewsWire - Nasdaq) Explore the comprehensive report detailing 11+ companies and pipeline drugs. Key areas include drug profiles, clinical stages, and therapeutic assessments. Discover emerging therapeutics from major players like Oryzon Genomics and 4SC.

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Lysine Specific Demethylase 1 Inhibitors - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.

The "Lysine Specific Demethylase 1 (LSD-1) Inhibitor - Pipeline Insight, 2025" report offers extensive insights into the landscape, revealing critical developments from over 11 companies and 11+ pipeline drugs. This report covers both clinical and nonclinical stage products, giving a detailed examination of therapeutics by product type, developmental stage, administration route, and molecule type. Additionally, it highlights inactive pipeline products within this domain.

The discovery of LSD-1, a histone demethylase conserved across species from yeasts to mammals, has positioned it as a crucial target for addressing malignancies related to its overexpression. Its inhibition opens promising avenues for cancer treatment and disorders closely tied to its activity.

The report highlights that companies and academic institutions are scrutinizing challenges and unearthing opportunities influencing LSD-1 Inhibitor research and development. Current developmental endeavors focus on innovative therapeutic approaches.

Emerging Drugs and Key Players

Key companies actively developing LSD-1 Inhibitors include Oryzon Genomics, 4SC, Salarius Pharmaceuticals, Celgene Corporation, Taiho Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, Beatica, and Rasna Therapeutics. Notable drugs in development comprise: ORY-2001, an oral drug in Phase II trials for various neurological and viral conditions; Domatinostat from 4SC, targeting cancers like Gastrointestinal cancer and Merkel cell carcinoma; alongside others such as ORY-3001, Seclidemstat, CC-90011, TAS-1440, SYHA-1807, and RASP-201, representing a spectrum of therapeutic exploration.

Therapeutic assessments are categorized by multiple parameters including developmental phase (Phase III to Discovery), routes of administration (oral, intranasal, subcutaneous, etc.), and molecule types (small molecules, monoclonal antibodies). This aids in understanding current and future market dynamics.

Pipeline Development Activities

The report delves into active collaborations, mergers, acquisitions, and licensing initiatives, highlighting their impact on emerging LSD-1 Inhibitor drugs. A thorough therapeutic assessment offers insights into pipeline capabilities and strategic industry maneuvers.

Insights and Assessments

The report's insights encompass pipeline analysis, therapeutic needs, drug impact, and unmet needs in cancer treatment. Key questions addressed involve the number of companies developing LSD-1 Inhibitors, emerging drugs in different stages, strategic collaborations, and the trajectory of clinical studies.

Overall, this comprehensive report serves as a crucial resource for stakeholders to understand the LSD-1 Inhibitor pipeline, market prospects, and competitive landscape as they prepare for 2025 and beyond.

Key Topics Covered
Introduction
Executive Summary
Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Overview

• Structure
• Mechanism of Action

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration

Lysine Specific Demethylase 1 (LSD-1) Inhibitor - The Publisher's Analytical Perspective
In-depth Commercial Assessment

• Lysine Specific Demethylase 1 (LSD-1) Inhibitor companies' collaborations, Licensing, Acquisition -Deal Value Trends

Lysine Specific Demethylase 1 (LSD-1) Inhibitor Collaboration Deals

• Company-Company Collaborations (Licensing/Partnering) Analysis
• Company-University Collaborations (Licensing/Partnering) Analysis

Late Stage Products (Phase III)

• Comparative Analysis

Drug name: Company name

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

ORY-2001: Oryzon Genomics

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I/II)

• Comparative Analysis

Seclidemstat: Salarius Pharmaceuticals

• Product Description
• Research and Development
• Product Development Activities

Pre-clinical and Discovery Stage Products

• Comparative Analysis

Research programme - small molecule therapeutics: Beatica

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

Lysine Specific Demethylase 1 (LSD-1) Inhibitor Key Companies
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Key Products
Lysine Specific Demethylase 1 (LSD-1) Inhibitor - Unmet Needs
Lysine Specific Demethylase 1 (LSD-1) Inhibitor - Market Drivers and Barriers
Lysine Specific Demethylase 1 (LSD-1) Inhibitor - Future Perspectives and Conclusion
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Analyst Views
Lysine Specific Demethylase 1 (LSD-1) Inhibitor Key Companies
Appendix
A selection of companies mentioned in this report includes, but is not limited to:

• Oryzon Genomics
• 4SC
• Salarius Pharmaceuticals
• Celgene Corporation
• Taiho Pharmaceutical
• CSPC ZhongQi Pharmaceutical Technology
• Beatica
• Rasna Therapeutics

For more information about this clinical trials report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN08052025004107003653ID1109523404